FDA may pull authorization of Pfizer’s Covid vaccine for children under 5

FDA may pull authorization of Pfizer’s Covid vaccine for children under 5


A nurse prepares doses of the Pfizer vaccine during a COVID-19 vaccination event at Josephine’s Southern Cooking in Chatham, Illinois, Dec. 30, 2021.

Brian Cassella | Tribune News Service | Getty Images

The Food and Drug Administration is weighing revoking its authorization of Pfizer‘s Covid-19 vaccine for healthy children under the age of 5, the drugmaker confirmed to CNBC on Tuesday. 

The move could leave many kids with no available shot against the virus, as jabs from Moderna and Novavax are cleared for more limited populations. While Covid typically causes mild symptoms in most children, others, such as infants under 1 or those with certain health conditions, can be at a higher risk of severe illness and hospitalization.

If the FDA pulls the authorization, it would add to a string of recent efforts by U.S. health agencies to change and undermine immunization policy since Health and Human Services Secretary Robert F. Kennedy Jr. — a prominent vaccine skeptic — took the helm. HHS did not immediately respond to a request for comment.

The FDA told Pfizer it might not renew its longstanding emergency use authorization for children aged 6 months to 4 years, the company said in a statement. Pfizer said it has requested the authorization to remain in place for the upcoming fall and winter season and is “currently in discussions with the agency on potential paths forward.”

The company said that the FDA’s “deliberations” are not related to the safety and efficacy of the shot, “which continues to demonstrate a favorable profile.”

The Guardian first reported on the FDA’s potential move. Moderna is working with the Centers for Disease Control and Prevention to boost supplies of its own Covid shot for children, the Guardian reported on Saturday.

In July, the FDA granted full approval to Moderna’s Covid vaccine for children — but only for those with health conditions that may put them at increased risk of severe illness if they become infected. Both shots from Moderna and Pfizer user messenger RNA technology.

Kennedy has targeted those vaccines in the past, filing a petition in May 2021 demanding that the agency revoke authorization of the jabs.  

Meanwhile, Novavax‘s protein-based shot has never been available for children under 12. 

In May, Kennedy announced that the Centers for Disease Control and Prevention has removed its recommendation of Covid vaccines for healthy children and pregnant women. 

But in updated guidance days later, the CDC said the shots “may” be given to those kids if a doctor agreed that it was necessary. Covid vaccines during pregnancy are now listed as “No Guidance/Not Applicable,” where they were previously recommended for all pregnant adults.



Source

Making U.S. biotech more competitive with China’s could help rare disease patients, experts say
Health

Making U.S. biotech more competitive with China’s could help rare disease patients, experts say

The growth of China’s biotechnology sector has been staggering. Beijing is pumping money into the industry, backing research efforts and helping launch a new wave of labs and incubators in the country. That’s a problem for the U.S. biotech industry and also affects rare disease patients who are waiting for a cure. Among the experts […]

Read More
Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference
Health

Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference

A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Good morning from San Francisco! It’s day three of the annual JPMorgan Healthcare Conference – the biggest gathering of biotech and pharma execs, investors and analysts in […]

Read More
OpenAI acquires health-care technology startup Torch
Health

OpenAI acquires health-care technology startup Torch

OpenAI has acquired the health-care technology startup Torch, the company announced on Monday. Torch was building a “unified medical memory” for artificial intelligence that aimed to bring a patient’s health data, which is typically siloed and stored across a number of different vendors and formats, into one place. Torch’s employees will join OpenAI as part […]

Read More